Method and device for predicting content change of medicine in living body

Through physiological pharmacokinetic model, the kinetic process of drugs in organisms was simulated, which solved the problem of the duration of animal experiments and the in vitro experiments that could not simulate in vivo dynamics, and achieved accurate prediction of drug toxicity characteristics and dose, reducing the experiment Cost and uncertainty.

CN119028603AActive Publication Date: 2024-11-26INST OF QUALITY STANDARD & TESTING TECH FOR AGRO PROD OF CAAS

Patent Information

Application Number
CN202411497995.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-25
Publication Date
2024-11-26
Estimated Expiration
2044-10-25

AI Technical Summary

Technical Problem

In the prior art, animal experiments are time-consuming and costly. In vitro tissue and cell culture cannot effectively simulate the kinetic process of drugs in the body, resulting in uncertainty issues in the extrapolation of toxic doses into the body, especially in the absence of toxicity information. It is difficult to design experiments in situations.

Method used

A method to predict the changes in the content of drugs in organisms was developed. By obtaining the in vitro kinetic parameters, physical and chemical properties parameters and physiological parameters of organisms, the physiological pharmacokinetic models were used to simulate the kinetics of drugs in vivo. The process, including the gastrointestinal tract, small intestine, liver, rapid perfusion of tissue, fat and blood, calculates the maximum rate of enzyme reactions of drugs in these areas and the Michter constant, and then predicts the changes in the content of drugs in the organisms.

Benefits of technology

It effectively solved the problem that the time spent in animal experiments and in vitro experiments cannot simulate the dynamic process in vivo, accurately predict the toxic characteristics and dose of drugs in organisms, reduces the experimental cost, and improves the certainty of toxic doses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119028603A_ABST
    Figure CN119028603A_ABST
Patent Text Reader

Abstract

The invention discloses a method and a device for predicting the content change of a drug in a living body. According to the method, a kinetic reaction system of a test substance is constructed in vitro by using the microparticles, so that the test substance fully reacts in the microparticles, and reaction conditions for carrying out an in-vitro kinetic experiment by using the microparticles are determined. Through the constructed microsome reaction system, the metabolic rate of a test substance in the liver and / or small intestine of an organism is calculated, a computer is utilized to compile metabolic kinetic parameters into a calculus equation, then the calculus equation is solved, and finally the kinetic process of the test substance is obtained. Therefore, the defect that toxicity experiments are carried out by using in-vitro biological tissue bodies is overcome. On the premise that animal experiments do not need to be carried out, the toxicity characteristics of the medicine in the mouse liver can be analyzed, and the dosage generating hepatotoxicity can be predicted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of food safety detection, and in particular relates to a method and a device for predicting changes in drug content in a living body. Background Art

[0002] In the field of food safety, it is necessary to conduct toxicity evaluation of contaminants present in food to ensure the health and safety of consumers. Generally, toxicity evaluation experiments are conducted using mice. However, animal experiments are time-consuming and costly, and it is difficult to quickly obtain the toxicity characteristics and toxic doses of contaminants. On the other hand, if faced with a new type of contaminant, it is impossible to design experimental doses to conduct animal experiments in the absence of its toxicity information and data. In order to make up for the shortcomings of animal toxicity experiments, in vitro tissue and cell culture have become the main method for judging the toxic effects of pollutants. However, in vitro experiments lack the kinetic process of simulating the absorption, distribution, metabolism and excretion of substances in the body, so there is an uncertainty problem in the extrapolation of in vitro experimental toxic doses to in vivo toxic doses.

[0003] At present, acute hepatotoxicity evaluation is mainly carried out using mice. When conducting experiments, the median lethal dose of a test compound is generally determined. The basic method is to give the test substance to many groups of mice at a series of doses, observe and record the number of animals that die in each group within a certain period of time, and then use statistical methods to calculate the dose that can kill 50% of a group of animals. The number of mice used is generally 10 per group, at least 6, and 6 dose groups should generally be set. If the set dose cannot reach the number of animal deaths, adjust and try again until it meets the requirements. The observation period for acute toxicity of animals should last until most animals that have typical symptoms of poisoning but have not died have fully recovered, generally 24 to 48 hours. Record the number of animal deaths during the observation period. After observation, it is best to keep the animals for 1 week. If poisoning symptoms or death occur 24 hours after the test substance is administered, it indicates delayed toxicity. The observation period should be extended to 2 weeks or 4 weeks. From the above, it can be seen that using mice to conduct acute animal toxicity experiments is not only time-consuming and costly, but most of the time it takes multiple experiments to achieve the desired result.

[0004] At present, in vitro tissue and cell culture are mainly used to replace animal toxicity tests internationally. However, in vitro tissue culture cannot simulate the kinetic processes of absorption, distribution, metabolism and excretion of the test substance in the body, which often leads to uncertainty in the extrapolation of in vitro experimental toxic doses to actual in vivo toxic doses (Groothuis, FA, Heringa, MB, Nicol, B., Hermens, JL, Blaauboer, BJ, Kramer, NI (2015). Dosemetric considerations in in vitro assays to improve quantitative in vitro–invivo dose extrapolations. Toxicology, 332, 30-40.; Algharably, EAH, Kreutz, R., Gundert-Remy, U. (2019). Importance of in vitro conditionsformodeling the in vivo dose in humans by in vitro–in vivo extrapolation(IVIVE). Archives of Toxicology, 93(3), 615-621.). Summary of the invention

[0005] In order to fully solve the problem that in vitro experiments cannot simulate the kinetic process of the test substance in vivo, the present invention has developed a device (system) that can replace the acute hepatotoxicity experiment in mice. Without the need for animal experiments, it can analyze the toxicity characteristics of drugs in the mouse liver and predict the dose that produces liver toxicity.

[0006] Thus, the first aspect of the present invention provides a method for predicting changes in the content of a drug in a living body, comprising: Obtain the in vitro kinetic parameters of the test substance, the physicochemical property parameters of the test substance and the physiological parameters of the organism, calculate the maximum enzyme reaction rate of the test substance in the liver and / or small intestine according to the in vitro kinetic parameters of the test substance, and then predict the content change of the test substance in the organism through the physiologically based pharmacokinetics (PBK) model that simulates the kinetic process of the drug in vivo; Wherein, the compartment structures of the physiological pharmacokinetic model simulating the kinetic process of the drug in vivo include: gastrointestinal tract, small intestine, liver, slowly perfused tissue, quickly perfused tissue, fat and / or blood; The in vitro kinetic parameters of the test substance include the maximum enzyme reaction rate of the test substance in the in vitro microsomes and the Michaelis constant of the test substance in the in vitro microsomes.

[0007] In the present invention, the microsomes include liver microsomes and small intestinal microsomes.

[0008] In the present invention, the content change of the test substance in the organism includes the content change of the test substance in the small intestine, liver, fat, fast perfusion tissue, slow perfusion tissue and / or blood.

[0009] The maximum enzyme reaction rate of the test substance in the in vitro microsomes and the Michaelis constant of the test substance in the in vitro microsomes are calculated based on the in vitro microsome experiments of the test substance.

[0010] In the present invention, according to the metabolism of the test substance at different time points in the in vitro microsome experiment, the time-concentration change curve is obtained, and the maximum enzyme reaction rate Vmax and the Michaelis constant Km of the test substance in the microsome can be calculated using the Michaelis equation. Michaelis equation: V = Vmax × [S] / (Km + [S]), where S is the concentration of the test substance.

[0011] In the present invention, the maximum enzyme reaction rate of the test substance in the liver is VMaxLM1 (µmol / h) = VMaxLM1c / 1000×60×MPL×L×BW, where MPL is 35 mg of microsomes per gram of liver (mg / g liver), L is the liver weight index = VLC×1000 (g / kg bw), and VmaxLM1c is the maximum enzyme reaction rate of the test substance in in vitro liver microsomes (nmol min -1 (mg protein) -1 ), BW is the body weight (kg) of the organism. In a specific embodiment of the present invention, the test substance is seneciopine, the organism is a mouse, and the value of VmaxLM1c is 7.948 obtained through a liver microsome experiment. The Michaelis constant KmLM1 of seneciopine in in vitro liver microsomes = 166.3 (µmol / L). The value of the Michaelis constant is involved in the calculation of the metabolic concentration change of seneciopine in the liver.

[0012] In the present invention, the maximum enzyme reaction rate of the test substance in the small intestine is VMaxSiM2 (µmol / h) = VMaxSiM2c / 1000×60×MPSi×Si×BW, wherein MPSi is 20.6 mg of microsomes per gram of small intestine (mg / g smallintestine), Si is the small intestine weight index = VSic×1000 (g / kg bw), VmaxSiM2c is the maximum enzyme reaction rate of the test substance in the small intestinal microsome (nmol min -1 (mg protein) -1 ), BW is the body weight (kg). In a specific embodiment of the present invention, the test substance is seneciopine, the organism is a mouse, and the value of VmaxSiM2c is 0.06577 obtained through a liver microsome experiment. The Michaelis constant KmSiM2=434.2 (µmol / L) of seneciopine in small intestinal microsomes. The value of the Michaelis constant is involved in the calculation of the metabolic concentration change of seneciopine in the small intestine.

[0013] In the present invention, the blood includes venous blood and arterial blood.

[0014] In the present invention, the organism includes mammals and humans. The mammals include but are not limited to mice and rats. As a preferred embodiment, the organism is a mouse.

[0015] According to a specific embodiment of the present invention, the physicochemical property parameters of the test substance include the absorption rate constant Ka (h -1 ), molecular weight of the test substance MWL (g / mol), partition coefficient of the test substance between liver and blood PLL, partition coefficient of the test substance between fat and blood PFL, partition coefficient of the test substance between rapidly perfused tissues and blood PRL, partition coefficient of the test substance between slowly perfused tissues and blood PSL, partition coefficient of the test substance between small intestine and blood PIL, content of the test substance in gastrointestinal tract AGI.

[0016] In the present invention, the content of the test substance in the gastrointestinal tract AGI is equal to the content of the test substance exposed orally.

[0017] In the present invention, the absorption rate constant Ka of the test substance in the intestine is calculated based on the permeability and molecular properties of the test substance in the small intestine.

[0018] In the present invention, the equation for calculating Ka is: log Papp=-5.469+0.236 log P; log Pappseneciphylline / Ka seneciphylline=log Papp adonifoline / 0.6.

[0019] In the present invention, the calculation method of Ka is derived from: TJ Hou, W. Zhang, K. Xia, XB Qiao, XJ Xu. ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties J. Chem. Inf. Comput. Sci., 44(2004), pp. 1585-1600.

[0020] In the present invention, the partition coefficient is obtained according to the octanol-water partition coefficient Kow of the test substance, and the calculation method is obtained according to the reference: J. DeJongh, HJ Verhaar, JL Hermens. A quantitativeproperty-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch.Toxicol., 72 (1997), pp. 17-25.

[0021] According to a specific embodiment of the present invention, the physiological parameters of the organism include body weight BW (kg), fat tissue volume fraction VFc, liver volume fraction VLc, small intestine volume fraction VSic, arterial blood volume fraction Vac, venous blood volume fraction VVc, blood volume fraction VBc, fast perfusion tissue volume fraction VRc, slow perfusion tissue volume fraction VSc, fat tissue volume VF (L or Kg), liver volume VL (L or Kg), small intestine volume VSi (L or Kg), fast perfusion tissue volume VR (L or Kg), slow perfusion tissue volume VS (L or Kg), arterial blood volume VA (L or Kg), venous blood volume VV (L or Kg), blood volume VB (L or Kg), blood flow to fat fraction QFc, blood flow to liver fraction QLc, blood flow to small intestine fraction QSic, blood flow to fast perfusion tissue fraction QRc, blood flow to slow perfusion tissue fraction QSc, cardiac output QC (L / h), adipose tissue blood flow QF (L / h), liver blood flow QL (L / h), small intestine blood flow QSi (L / h), fast perfusion tissue blood flow QR (L / h), slow perfusion tissue blood flow QS (L / h).

[0022] In the present invention, the physiological parameters of the organism are obtained by searching the literature. In a specific embodiment of the present invention, the organism is a mouse. The physiological parameters of the mouse are referenced in: Brown, RP, Delp, MD, Lindstedt, SL, Rhomberg, LR, Beliles, RP, 1997. Physiological Parameter Values ​​for Physiologically Based Pharmacokinetic Models. Toxicol Ind Health. 13, 407-484.

[0023] In the present invention, the physiological parameters of the mice are specifically as follows: mouse body weight BW=0.025 (Kg); fat tissue fraction VFc=0.07; liver fraction VLc=0.034; small intestine fraction VSic=0.014; arterial blood fraction VAc=0.0185; venous blood fraction VVc=0.0555; fast perfusion tissue fraction VRc=0.09-VLc-VSic; slow perfusion tissue fraction VSc=0.82-VFc; fat tissue volume VF=VFc×BW(L or kg); liver volume VL=VLc×BW(L or Kg); small intestine volume VSi=VSic×BW(L or Kg); fast perfusion tissue volume VR=VRc×BW(L or Kg); slow perfusion tissue volume VS=VSc×BW(L or Kg); arterial blood volume VA=VAc×BW(L or Kg); venous blood volume VV=VVc×BW(L or Kg); cardiac output QC=15×BW^0.74(L / h); blood flow fraction to fat QFc=0.09; blood flow fraction to liver QLc=0.25-QSic; blood flow fraction to small intestine QSic=0.183; blood flow fraction to fast perfused tissues QRc=0.76-QLc-QSic; blood flow fraction to slow perfused tissues QSc=0.24-QFc; fat tissue blood flow QF=QFc×QC(L / h); liver blood flow QL=QLc×QC(L / h); small intestine blood flow QSi=QSic×QC(L / h); fast perfused tissue blood flow QR=QRc×QC(L / h); slow perfused tissue blood flow QS=QSc×QC(L / h).

[0024] According to a specific embodiment of the present invention, the physiological pharmacokinetic model that simulates the kinetic process of the drug in vivo is established using a general calculus equation solver, and the physiological pharmacokinetic model contains a mass conservation differential equation that describes the dynamic changes in the content of the test substance in each chamber structure every hour.

[0025] In the present invention, the physiologically based pharmacokinetics (PBK) model for simulating the kinetic process of drugs in vivo is a mathematical model, which includes a plurality of calculus equations and is used to describe the changes in the content of drugs in the organism over time.

[0026] In the present invention, a general calculus equation solver is used to solve the mass conservation differential equation describing the dynamic change of the test substance content in each chamber structure every hour, and the dynamic change of the test substance content in each chamber structure every hour is obtained.

[0027] In the present invention, the universal calculus equation solver includes but is not limited to Berkeley Madonna, Matlab, Gastro, and Simcyp.

[0028] According to a specific implementation of the present invention, the universal calculus equation solver is BerkeleyMadonna.

[0029] According to a specific embodiment of the present invention, the model for simulating the kinetic process of a drug in vivo comprises a plurality of submodules, each of which is used to describe the kinetic process of the test drug in different tissues or organs.

[0030] According to a specific embodiment of the present invention, the physiological pharmacokinetic model for simulating the kinetic process of a drug in vivo comprises the following submodules: The gastrointestinal simulation module is used to calculate the concentration change before and after the test substance enters the gastrointestinal tract for reaction. It performs the following calculation: the dynamic change of the test substance metabolite content in the small intestine per hour AMSiM2' (µmol / h) = VmaxSiM2×CVSi / (KmSiM2+CVSi), where CVSi is the concentration of the test substance flowing into the venous blood after metabolism in the small intestine (µmol / L) = CSi / PIL, where the distribution coefficient of the test substance in the small intestine and blood PIL = 1.04, and CSi (µmol / L) is the concentration of the test substance in the small intestine = ASi / VSi, ASi is the content of the test substance in the small intestine (µmol); VSi is the volume of the small intestine (L).

[0031] The initial content of the test substance in the small intestine is 0: Init ASi = 0; The initial concentration of metabolites produced by the test substance in the small intestine is 0: Init AMSiM2 =0.

[0032] The liver simulation module is used to calculate the change in the concentration of the test substance before and after the test substance flows out of the gastrointestinal tract and enters the liver. It executes the following formula: the change in the content of the metabolite of the test substance in the liver per hour AMLM1' (µmol / h) = VmaxLM1×CVL / (KmLM1+CVL), where CVL is the concentration of the test substance flowing into the venous blood after metabolism in the liver (µmol / L) = CL / PLL, where the distribution coefficient of the test substance in the liver and blood PLL = 1.04, and CL is the concentration of the test substance in the liver (µmol / L) = AL / VL, AL is the content of the test substance in the liver (µmol), and VL is the liver volume (L).

[0033] The initial content of the test substance in the liver is 0: Init AL = 0; The initial level of metabolites produced by the test substance in the liver is 0: Init AMLM1 = 0.

[0034] The fat simulation module is used to calculate the concentration change of the test substance before and after it enters the fat. It performs the following calculation: the concentration of the test substance flowing into the venous blood after metabolism in the fat CVF (µmol / L) = CF / PFL, where the distribution coefficient of the test substance between fat and blood PFL = 1.70, where CF is the concentration of the test substance in the fat (µmol / L) = AF / VF, AF is the content of the test substance in the fat (µmol), and VF is the fat volume (L).

[0035] The initial total amount of the test substance in the fat is 0: Init AF = 0.

[0036] The rapid perfusion tissue simulation module is used to calculate the concentration change of the test substance before and after entering the rapid perfusion tissue. It performs the following calculation: the concentration of the test substance flowing into the venous blood after metabolism in the rapid perfusion tissue CVR (µmol / L) = CR / PRL, where the distribution coefficient of the test substance in the rapid perfusion tissue and blood PRL = 1.04, where CR is the concentration of the test substance in the rapid perfusion tissue (µmol / L) = AR / VR, AR is the content of the test substance in the rapid perfusion tissue (µmol), and VR is the volume of the rapid perfusion tissue (L).

[0037] The initial content of the test substance in the rapidly perfused tissue is 0: Init AR = 0.

[0038] The slow perfusion tissue simulation module is used to calculate the concentration change of the test substance before and after entering the fast perfusion tissue. It performs the following calculation: the concentration of the test substance flowing into the venous blood after metabolism in the slow perfusion tissue CVS (µmol / L) = CS / PSL, where the distribution coefficient of the test substance in the slow perfusion tissue and blood PSL = 1.02, where CS is the concentration of the test substance in the slow perfusion tissue (µmol / L) = AS / VS, AS is the content of the test substance in the slow perfusion tissue (µmol), and VS is the volume of the slow perfusion tissue (L).

[0039] The initial content of the test substance in the slowly perfused tissue is 0: Init AS = 0.

[0040] The blood simulation module is used to calculate the concentration change of the test substance in the blood, and it performs the following calculation formula: The concentration of the test substance in arterial blood is equal to the concentration in venous blood CA = CV; The initial content of the test substance in venous blood is 0: Init AB = 0.

[0041] The change in the concentration of the test substance in the blood is CB = AB / VB, where AB is the test substance content in the blood and VB is the blood volume.

[0042] Draw a curve with time as the horizontal axis and CB as the vertical axis.

[0043] The initial maximum area under the curve of the test substance in blood is 0: init AUC = 0.

[0044] The dynamic change of the maximum area under the curve of the test substance in the blood AUC' = CB×Time.

[0045] According to a specific embodiment of the present invention, the mass conservation differential equation describing the dynamic change of the test substance content in the small intestine per hour is shown in formula (1): ASi' = QSi×(CB-CVSi) + Ka×AGI-AMSiM2'(1), Among them, ASi' is the dynamic change of the content of the test substance in the small intestine per hour (µmol / h), QSi is the small intestinal blood flow (L / h), CB is the concentration of the test substance in the blood (µmol / L), CVSi is the concentration of the test substance flowing into the venous blood after metabolism in the small intestine (µmol / L), Ka is the absorption rate constant of the test substance in the intestine (h -1 ), AGI is the content of the test substance in the gastrointestinal tract (µmol), and AMSiM2' is the dynamic change of the content of the metabolite of the test substance in the small intestine per hour.

[0046] The mass conservation differential equation describing the dynamic change AL' of the test substance content in the liver every hour is shown in formula (2): AL' = QL×CB +QSi×CVSi-(QL+QSi)×CVL-AMLM1'(2), Among them, AL' is the dynamic change of the test substance content in the liver per hour (µmol / h), QL is the liver blood flow (L / h), QSi is the small intestine blood flow (L / h), CVSi is the concentration of the test substance flowing into the venous blood after metabolism in the small intestine (µmol / L), CVL is the concentration of the test substance flowing into the venous blood after metabolism in the liver (µmol / L), and AMLM1' is the dynamic change of the content of the test substance metabolite in the liver per hour.

[0047] According to a specific embodiment of the present invention, the dynamic change of the content of the metabolite of the test substance in the small intestine per hour is expressed according to the following formula (3): AMSiM2'=VmaxSiM2×CVSi / (KmSiM2+CVSi)(3), where VmaxSiM2 is the maximum enzyme reaction rate of the test substance in the small intestine (µmol / h), and KmSiM2 is the Michaelis constant of the test substance in the in vitro small intestinal microsomes (µmol / L).

[0048] According to a specific embodiment of the present invention, the dynamic change of the content of the metabolite of the test substance in the liver per hour is expressed according to the following formula (4): AMLM1'=VmaxLM1×CVL / (KmLM1+CVL)(4), where VmaxLM1 is the maximum enzyme reaction rate of the test substance in the liver (µmol / h), and KmLM1 is the Michaelis constant of the test substance in in vitro liver microsomes (µmol / L).

[0049] According to a specific embodiment of the present invention, the dynamic change of the content of the test substance in fat per hour is expressed according to the following formula (5): AF'=QF×(CB-CVF)(5), Among them, AF' is the dynamic change of the content of the test substance in fat per hour (µmol / h), QF is the blood flow of adipose tissue (L / h), and CVF is the concentration of the test substance flowing into venous blood after metabolism in fat (µmol / L).

[0050] The dynamic changes of the test substance content in the rapidly perfused tissue every hour are expressed according to the following formula (6): AR'=QR×(CB-CVR)(6), Among them, AR' is the dynamic change of the content of the test substance in the rapidly perfused tissue per hour (µmol / h), QR is the blood flow of the rapidly perfused tissue (L / h), and CVR is the concentration of the test substance flowing into the venous blood after metabolism in the rapidly perfused tissue (µmol / L).

[0051] The dynamic changes of the test substance content in the slow perfusion tissue per hour are expressed according to the following formula (7): AS'=QS×(CB-CVS)(7), Among them, AS' is the dynamic change of the content of the test substance in the slow perfusion tissue per hour (µmol / h), QS is the blood flow of the slow perfusion tissue (L / h), and CVS is the concentration of the test substance flowing into the venous blood after metabolism in the slow perfusion tissue (µmol / L).

[0052] The dynamic changes of the test substance content in the blood per hour are expressed according to the following formula (8): AB'=(QF×CVF+(QL+QSi)×CVL+QR×CVR+QS×CVS-QC×CB)(8), where AB' is the dynamic change of the test substance content in the blood per hour (µmol / h), and QC is the cardiac output (L / h).

[0053] According to a specific embodiment of the present invention, the method further comprises drawing a time-concentration change curve of the test substance in the organism.

[0054] According to a specific embodiment of the present invention, the test substance is a Senecio drug. According to a specific embodiment of the present invention, the test substance is Senecio phenanthemine.

[0055] The second aspect of the present invention provides a device for predicting changes in drug content in a living body, which uses the method described in the first aspect of the present invention to predict changes in drug content in a living body, and the device comprises: A data input module, used to input the kinetic parameters of the test substance, the physicochemical property parameters of the test substance and the physiological parameters of the organism, wherein the in vitro kinetic parameters of the test substance include the maximum enzyme reaction rate and the Michaelis constant of the test substance in in vitro microsomes, the microsomes include liver microsomes and / or small intestinal microsomes, and the maximum enzyme reaction rate and the Michaelis constant of the test substance in in vitro microsomes are calculated based on in vitro microsome experiments of the test substance; A data preprocessing module is used to calculate the maximum enzyme reaction rate of the test substance in the liver and small intestine according to the in vitro kinetic parameters of the test substance; The model prediction module is used to predict the concentration change of the test substance in the organism through the physiological pharmacokinetic model that simulates the kinetic process of the drug in the body as described in the first aspect of the present invention.

[0056] According to a specific embodiment of the present invention, the data preprocessing module performs the calculation of the following formula: The maximum rate of enzyme reaction of the test substance in the liver is VMaxLM1 (µmol / h) = VMaxLM1c / 1000×60×MPL×L×BW, or the maximum rate of enzyme reaction of the test substance in the small intestine is VMaxSiM2 (µmol / h) = VMaxSiM2c / 1000×60×MPSi×Si×BW.

[0057] In some embodiments, the device further comprises an output module for outputting a threshold value of liver damage caused by the test substance.

[0058] A third aspect of the present invention provides an electronic device, comprising a processor and a memory, wherein the memory stores an execution code, and when the executable code is executed by the processor, the processor executes the method described in the first aspect of the present invention.

[0059] A fourth aspect of the present invention provides a computer-readable storage medium having executable code stored thereon. When the executable code is executed by a processor of an electronic device, the processor is caused to execute the method described in the first aspect of the present invention.

[0060] Beneficial effects: The advantages of the present invention are that it can solve the shortcomings of animal experiments that are time-consuming and expensive, and can effectively solve the problem that in vitro cell and tissue culture cannot simulate the kinetic process of absorption, distribution, metabolism and excretion of the test substance, and can effectively solve the uncertainty problem of extrapolating the in vitro toxic dose to the in vivo toxic dose. If only animal experiments are done, especially for drugs with relatively insufficient toxicity data or information, it is difficult to successfully obtain its toxic characteristics and toxic dose in mice through a single experiment. In vitro cell or tissue culture cannot obtain the kinetic process of the test substance, resulting in the unknown concentration at which it truly exerts toxic effects in vivo. In view of the shortcomings of in vivo animal experiments and in vitro toxicity experiments, the present invention uses the liver / intestinal microsomes of mice to build a kinetic reaction system that can simulate the metabolic transformation of the test substance in the liver / intestinal tract, and uses a computer to model the physiological parameters of mice, the physicochemical parameters of the test substance and the kinetic parameters of the test substance, and the model can simulate and analyze the absorption, distribution, metabolism and excretion process of the test substance in the mouse liver and body, the concentration in each organ and the concentration change in the blood and other in vivo toxic characteristics. On this basis, the model constructed by the present invention can be used to correct and analyze the toxicity data of the test substance obtained by in vitro tissue or cell culture, and solve the uncertainty problem of extrapolating the in vitro toxic dose to the in vivo toxic dose. Therefore, the present invention effectively solves the problem of long cycle and high cost of acute liver toxicity in animals by combining biological means with computer modeling, and effectively solves the problem that in vitro toxicity experiments cannot simulate the kinetic process of absorption, distribution, metabolism and excretion of the test substance in vivo.

[0061] The key point of the present invention is to build a calculus equation for predicting liver toxicity in mice by building a model. In order to successfully write this mathematical formula, the present invention uses mouse liver microsomes to build an in vitro liver kinetic reaction system. To successfully build this reaction system, it is necessary to optimize the time, concentration and liver microsome concentration of the test substance in the system to reach saturation, so as to construct a model that accurately predicts the toxic effects in the test subject. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 The model of the present invention predicts the toxic dose-effect relationship curve of seneciophylline in mice; Figure 2 It is a schematic diagram of the principle process of the present invention; Figure 3It is an organ compartment model; Figure 4 This is a comparison chart between the prediction results of the model of the present invention and the experimental results of mice. DETAILED DESCRIPTION

[0063] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0064] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0065] Unless otherwise specified, experimental methods, detection methods, and preparation methods not described in detail in the present invention all adopt conventional techniques in the technical field.

[0066] The present invention uses mouse liver microsomes to construct a kinetic reaction system of the test substance in vitro, allowing the test substance to fully react in the liver, and after optimizing different reaction times, liver microsome concentrations and test substance concentrations, the best reaction system for conducting in vitro kinetic experiments using liver microsomes is determined. The metabolic rate of the test substance in the liver is calculated through the constructed liver microsome reaction system, and the metabolic kinetic parameters of the test substance are written into a mathematical formula code using a computer, and then solved to finally obtain the kinetic process of the test substance. The principle and process of the present invention are as follows: Figure 2 shown.

[0067] Example 1 1. Use mouse microsomes to build an in vitro kinetic reaction system C57 mouse liver and small intestinal microsomes were purchased from CHI Scientific Inc. (Maynard, MA, USA). In vitro incubation reaction systems for liver and small intestine were established separately, containing 0.1 M potassium phosphate buffer (pH 7.4), NADPH regeneration system (5 mM MgCl2, 1 mM NADP +, 10 mM glucose-6-phosphate, 2 U / mL glucose-6-phosphate dehydrogenase), 2 mM GSH, 0.5 mg protein / mL C57 mouse liver or intestinal microsomes and the test substance (seneciophylline) 2-500 µM, the final volume of the reaction system is 100 µL. The reaction system was incubated in a water bath at 37°C, liver microsomes were incubated for 30 minutes, small intestinal microsomes were incubated for 2 hours, and then 100 µL of ice methanol was added to stop the reaction. Finally, the reaction system was centrifuged at 15,000 g for 10 minutes, and the supernatant was collected and detected by LC-MS / MS. The process is described by the Michaelis-Menten equation: V= Vmax×[S] / (Km + [S]). Based on the data of the change of the test substance concentration over time obtained from the in vitro microsome experiment of the test substance, the maximum enzyme reaction rate and Michaelis constant in the microsomes of the test substance were calculated.

[0068] 2. Body In order to accurately simulate the kinetic response of the test substance in mice, the present invention divides the model into two major parts, one is the body part and the other is the characteristic part of the test substance. The body part mainly describes the physiological characteristics of the experimental animal to be simulated by the model, including: body weight, blood perfusion rate, tissue and organ volume and percentage of body weight, etc., specifically: Mouse body weight BW = 0.0250 (Kg); adipose tissue fraction VFc = 0.07; liver fraction VLc = 0.034; Small intestinal fraction VSic = 0.014; Arterial blood fraction VAc = 0.0185; Venous blood fraction VVc = 0.0555; Rapidly perfused tissue fraction VRc = 0.09-VLc-VSic; Slowly perfused tissue fraction VSc = 0.82-VFc; Adipose tissue volume VF = VFc × BW (L or kg); Liver volume VL = VLc × BW; Small intestinal volume VSi = VSic × BW; Rapidly perfused tissue volume VR = VRc × BW; Slowly perfused tissue volume VS = VSc × BW; Arterial blood volume VA = VAc × BW; Venous blood volume VV = VVc × BW; Cardiac output QC = 15×BW^0.74 (L / h) (Brown, RP, Delp, MD, Lindstedt,SL, Rhomberg, LR, Beliles, RP(1997). Physiological Parameter Values ​​forPhysiologically Based Pharmacokinetic Models. Toxicol Ind Health. 13, 407-484.); The fraction of blood flow to fat, QFc = 0.09; The fraction of blood flowing to the liver is QLc = 0.25 -QSic; The fraction of blood flowing to the small intestine, QSic = 0.183; The fraction of blood flowing to rapidly perfused tissues is QRc = 0.76-QLc-QSic; The fraction of blood flowing to slowly perfused tissues is QSc = 0.24-QFc; Adipose tissue blood flow QF = QFc × QC (L / h); Liver blood flow QL = QLc × QC; Small intestinal blood flow QSi = QSic × QC; Rapid perfusion tissue blood flow QR = QRc × QC; Slowly perfused tissue blood flow QS = QSc×QC.

[0069] 3. Metabolic characteristics of the test substance According to the principle of mass conservation, the mass balance differential equation of the liver and small intestine is established to simulate the metabolic process of the test substance in the liver and calculate the inflow and outflow of the test substance in the liver and small intestine. Specifically, the metabolic process in the liver can be described as: The absorption rate constant of the test substance in the intestine is Ka = 0.55 / h (Hou, TJ, Zhang, W., Xia, K., Qiao, XB, Xu, XJ (2004). ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J Chem InfComput Sci. 44, 1585-1600); log Papp = -5.469 + 0.236 logP Each gram of mouse liver contains 35 mg of liver microsomal protein MPL = 35 (mg / g liver) (Malekinejad, H., Maas-Bakker, RF, Fink-Gremmels, J. (2005). Bioactivation ofzearalenone by porcine hepatic biotransformation. Veterinary Research, 36(5-6), 799-810.); Liver weight index L=VL C ×1000(g / kg bw); The maximum enzyme reaction rate of the test substance in liver microsomes is VmaxLM1c=7.948 (nmol min -1 (mgprotein) -1 ); The maximum enzyme reaction rate of the test substance in the liver is VMaxLM1 (µmol / h) = VMaxLM1c / 1000×60×MPL×L×BW; The Michaelis constant for the metabolism of the test substance in the liver was KmLM1 = 166.3 (µmol / L); In the present invention, the Michaelis constant of the metabolism of the test substance in the liver is characterized by its Michaelis constant in in vitro liver microsomes.

[0070] Small Intestine: Each gram of small intestine of mice contains 20.6 mg of microsomal protein MPSi=20.6 (mg / g small intestine); (Cubitt, HE, Houston, JB, Galetin, A. (2011). Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic andintestinal microsomal and cytosolic data. Drug metabolism and disposition, 39(5), 864-873.) Small intestine weight index Si =VSic×1000 (g / kg bw); The maximum enzyme reaction rate of the test substance in the small intestinal microsomes is VmaxSiM2c = 0.06577 (nmol min -1 (mgprotein) -1 ) ; The maximum rate of enzyme reaction of the test substance in the small intestine VMaxSiM2 (µmol / h) = VMaxSiM2c / 1000×60×MPSi×Si×BW; The Michaelis constant for the metabolism of the test substance in the small intestine was KmSiM2 = 434.2 (µmol / L); In the present invention, the Michaelis constant of the metabolism of the test substance in the small intestine is characterized by its Michaelis constant in the in vitro small intestinal microsomes.

[0071] After the metabolic process of the test substance in the liver and small intestine is described, a calculus equation is written based on the principle of mass conservation to describe the concentration changes of the test substance after it enters other organs and tissues through the bloodstream and then flows into the blood after metabolic reactions. Specifically: Fat: Dynamic changes of the test substance content in fat per hour AF' = QF × (CB-CVF) (unit: µmol / h); The initial content of the test substance in fat is 0 Init AF = 0; The concentration of the test substance in fat CF = AF / VF; The concentration of the test substance flowing into the venous blood after metabolism in fat is CVF = CF / PFL.

[0072] Rapid perfusion of tissue: Dynamic changes of the test substance content in the rapidly perfused tissue every hour AR' = QR×(CB-CVR), unit: µmol / h; The initial content of the test substance in the rapidly perfused tissue is 0 Init AR = 0; The concentration of the test substance in the rapidly perfused tissue is CR = AR / VR; The concentration of the test substance that flows into the venous blood after metabolism in the rapidly perfused tissue is CVR = CR / PRL.

[0073] Slowly perfused tissue: Dynamic changes of the test substance content in the slow perfused tissue per hour AS' = QS × (CB-CVS), unit: µmol / h; The initial content of the test substance in the slowly perfused tissue is 0 Init AS = 0; The concentration of the test substance in the slowly perfused tissue is CS = AS / VS; The concentration of the test substance that flows into the venous blood after metabolism in the slowly perfused tissue is CVS = CS / PSL.

[0074] After the above metabolic process characteristics are described, the model operation process is set up, and the various organs and tissues are connected in series through mathematical formulas, specifically: Model run settings: The molecular weight of the test substance is MWL = 333.38 (g / mol); Assume that the oral exposure content of the test substance GDOSE = 10 (mg / kg bw); The units of oral exposure to the test substance are converted into the concentration units of in vitro exposure: ODOSE = GDOSE×1E -3 / MWL×1E6 (µmol / kg bw); In vitro exposure concentration DOSE = ODOSE × BW (µmol); Model running start time Starttime = 0(h -1 ); Model running end time Stoptime = 24(h -1 ); Description of the metabolic process of the test substance in various organs and tissues through the bloodstream after oral administration: Oral exposure: Dynamic changes in the content of the test substance in the gastrointestinal tract per hour AGI' (µmol / h) = -ka×AGI; The initial concentration of the test substance in the gastrointestinal tract is equal to the in vitro exposure concentration Init AGI = dose; The dynamic change of the test substance content in the liver per hour AL' = QL×CB +QSi×CVSi - (QL+QSi)×CVL- AMLM1'; The concentration of the test substance flowing into the venous blood after liver metabolism is CVL = CL / PLL; Dynamic changes in the content of the test substance metabolites in the liver every hour AMLM1' = VmaxLM1×CVL / (KmLM1 +CVL); Dynamic changes of the test substance content in the small intestine per hour ASi' = QSi×(CB -CVSi) + ka×AGI -AMSiM2'; The concentration of the test substance flowing into the venous blood after intestinal metabolism is CVSi = CSi / PIL; Dynamic changes in the content of the test substance metabolites in the intestine every hour AMSiM2'= VmaxSiM2×CVSi / (KmSiM2 + CVSi); The concentration of the test substance in arterial blood is CA = CV; Dynamic changes of the test substance content in the blood every hour AB' = (QF×CVF + (QL+QSi)×CVL + QR×CVR + QS×CVS - QC×CB); The dynamic change of the area under the curve of the test substance in the blood every hour AUC' = CB×Time.

[0075] After the metabolic calculation formulas of the above organs and tissues are established, they are integrated into the Berkeley Madonna algorithm platform to realize the calculation of the above simulation process. The above algorithm platform includes the following modules: Data input module: used to input the kinetic parameters, physicochemical property parameters and mouse-related physiological parameters of the test substance; Data initial processing module: used to realize the extrapolation of in vitro liver microsome and small intestinal microsome reaction concentrations to the liver and small intestine concentrations in mice, and it performs the calculation of the following formula: Each gram of liver contains 35 mg of microsomes, MPL=35 (mg / g liver); Liver weight index L=VL C ×1000(g / kg bw); The maximum enzyme reaction rate of the test substance in liver microsomes is VmaxLM1c=7.948 (nmol min -1 (mgprotein) -1 ); The maximum enzyme reaction rate of the test substance in the liver is VMaxLM1 (µmol / h) = VMaxLM1c / 1000×60×MPL×L×BW; The Michaelis constant for the metabolism of the test substance in the liver was KmLM1 = 166.3 (µmol / L); Each gram of small intestine contains 20.6 mg of microsomes, MPSi = 20.6 (mg / g small intestine); Small intestine weight index Si = VSiC × 1000 (g / kg bw); The maximum enzyme reaction rate of the test substance in the small intestinal microsomes is VmaxSiM2c = 0.06577 (nmol min -1 (mgprotein) -1 ); The maximum rate of enzyme reaction of the test substance in the small intestine VMaxSiM2 (µmol / h) = VMaxSiM2c / 1000×60×MPSi×Si×BW; The Michaelis constant for the metabolism of the test substance in the small intestine was KmSiM2 = 434.2 (µmol / L).

[0076] The data simulation module includes the following submodules: Gastrointestinal simulation is used to calculate the change in the concentration of the test substance before and after the test substance enters the gastrointestinal tract for reaction. It is calculated using the following formula: The initial content of the test substance in the small intestine is 0 Init ASi = 0, The initial content of metabolites generated by the test substance in the small intestine is 0 Init AMSiM2 = 0, The concentration of the test substance in the small intestine CSi = ASi / VSi, The concentration of the test substance in the venous blood after metabolism in the small intestine is CVSi = CSi / PIL, The dynamic changes of metabolite content in the small intestine every hour AMSiM2'= VmaxSiM2×CVSi / (KmSiM2 +CVSi).

[0077] The liver simulation module is used to calculate the change in the concentration of the test substance before and after the test substance flows out of the gastrointestinal tract and enters the liver. It performs the following calculation formula: The initial content of the test substance in the liver is 0 Init AL = 0, The initial level of the test substance metabolite produced in the liver is 0 Init AMLM1 = 0, The concentration of the test substance in the liver CL = AL / VL, The concentration of the test substance in the venous blood after metabolism in the liver is CVL = CL / PLL. The dynamic changes of metabolite content in the liver every hour are AMLM1' = VmaxLM1×CVL / (KmLM1 + CVL).

[0078] The fat simulation module is used to calculate the concentration change of the test substance before and after it enters the fat. It performs the following calculation formula: The initial content of the test substance in fat is 0 Init AF = 0, The concentration of the test substance in fat CF = AF / VF, The concentration of the test substance in fat that flows into venous blood after metabolism is CVF = CF / PFL.

[0079] The rapid perfusion tissue simulation module is used to calculate the concentration change of the test substance before and after it enters the rapid perfusion tissue. It performs the following calculation formula: The initial content of the test substance in the rapidly perfused tissue is 0 Init AR = 0, The concentration of the test substance in the rapidly perfused tissue is CR = AR / VR. The concentration of the test substance that flows into the venous blood after metabolism in the rapidly perfused tissue is CVR = CR / PRL.

[0080] The slow perfusion tissue simulation module is used to calculate the concentration change of the test substance before and after it enters the fast perfusion tissue. It performs the following calculation formula: The initial content of the test substance in the slowly perfused tissue is 0 Init AS = 0, The concentration of the test substance in the slowly perfused tissue is CS = AS / VS, The concentration of the test substance that flows into the venous blood after metabolism in the slowly perfused tissue is CVS = CS / PSL.

[0081] The blood flow simulation module is used to calculate the concentration change of the test substance in the blood, and it performs the following calculation formula: The concentration of the test substance in arterial blood is equal to the concentration in venous blood CA = CV, The initial content of the test substance in the blood is 0 Init AB = 0, The concentration of the test substance in the blood CB = AB / VB, The initial maximum area under the curve of the test substance in the blood is 0 init AUC = 0, The dynamic change of the maximum area under the curve of the test substance in the blood is AUC' = CB×Time.

[0082] The result output module is used to output the predicted concentration of the test substance in various organs, tissues and blood after entering the body and the toxicity threshold that causes acute liver damage in mice. It is calculated by the following formulas: Dynamic changes of the content of the test substance in the small intestine ASi' = QSi×(CB -CVSi) + ka×AGI -AMSiM2', Dynamic changes of the content of the test substance in the liver AL' = QL×CB +QSi×CVSi - (QL+QSi)×CVL -AMLM1', Dynamic changes of the content of the test substance in fat: AF' = QF×(CB-CVF), Dynamic changes in the content of the test substance in the rapidly perfused tissue AR' = QR × (CB-CVR), Dynamic changes of the content of the test substance in the slow perfusion tissue AS' = QS × (CB-CVS), The dynamic changes of the test substance content in the blood AB' = (QF×CVF + (QL+QSi)×CVL + QR×CVR+ QS×CVS - QC×CB).

[0083] Figure 3This is the compartment model diagram of the physiologically based pharmacokinetic (PBK) model.

[0084] After running the established model using Berkeley Madonna, the time-concentration curve of the drug in the liver in vivo is obtained. The value under the curve is put into the BMD (Benchmark Dose) software for calculation and fitting, and the threshold of drug-induced liver toxicity can be obtained.

[0085] Upload the data to the BMD calculation software and set the parameters. The BMD software will automatically perform the fitting, and after fitting, the toxic dose-effect relationship curve of seneciophylline in mice is obtained.

[0086] Example 2 Verification Implementation Model verification includes two aspects: one is the verification of the model parameters themselves, and the other is the verification of the accuracy of the model's prediction results.

[0087] The validation of the model parameters is mainly carried out through sensitivity analysis. During the model operation, the value of each parameter is increased by 5% and then compared with the initial value. If the absolute value is greater than 0.1, and the error prompt of the model is less than 1, it means that the sensitivity of the parameter setting is high. The formula for sensitivity test is: SC = ((C′-C) / (P′-P))×(P / C).

[0088] The model of the present invention uses a pyrrolizidine alkaloid-senecioline to carry out model verification. According to the above steps and parameter input, all the relevant parameters of senecioline are input and executed into the written mathematical formula, and then the model is run. According to the formula of the sensitivity test, the SC value of each parameter is analyzed, and the sensitivity range of the model of the present invention is 0.3-1.0, and the error value of the operation is 0.1, indicating that the model parameters of the present invention are correctly set and the model operation is normal.

[0089] The sensitivity value of the model of the present invention ranges from 0.3 to 1.0, and the error value is 0.1. The toxic dose-effect relationship curve of seneciophylline predicted by this model in mice is as follows: Figure 1 shown.

[0090] The model prediction results were verified by comparing the results of the toxicity test on mice fed with different concentrations of senecioline. The results predicted by the present invention were compared with the results of the acute hepatotoxicity test on C57 BL / 6J male mice exposed to senecioline by single oral administration (Table 1).

[0091] Table 1 Experiment on acute hepatotoxicity of seneciophylline in mice

[0092] Source: Wang, W., Yang, X., Chen, Y., Ye, X., Jiang, K.,&Wang, Z. (2020). Seneciphylline, a main pyrrolizidine alkaloid in Gynura japonica, induceshepatotoxicity in mice and primary hepatocytes via activating mitochondria‐mediated apoptosis. Journal of Applied Toxicology, 40(11), 1534-1544. Michael J. Clayton. (2023). Relative hepatotoxicity, carcinogenicity, and toxic genomics of select dehydropyrrolizidine alkaloids in mice. PP:124. In order to verify the accuracy of the model of the present invention in predicting acute hepatotoxicity, the model of the present invention was used to predict the threshold of acute liver damage caused by the test substance in mice, and the prediction results showed that it was 11.6-33.7 mg / kg bw / day. In contrast to the acute hepatotoxicity experiment in mice, the threshold of liver cell necrosis observed in experiment 1 was 7-70 mg / kg bw / day, and the dose observed in experiment 2 when inflammation of the mouse liver was 2-4 mg / kg bw / day. Comparison of the results of the acute hepatotoxicity experiment in mice with the results of the hepatotoxicity threshold predicted by the model of the present invention ( Figure 4). The toxicity threshold ranges predicted by the model of the present invention all fall within the dosage range obtained in the mouse animal experiment, and the difference is within 10 times. According to the World Health Organization's "Principles for Assessing the Risks of Chemical Exposure to Human Health", when the model's extrapolation results deviate from the mouse in vivo experimental results by 3 to 10 times, the accuracy of the model's prediction results is deemed acceptable. (International Programme on Chemical Safety (IPCS). Principles for the assessment of risks to human health from exposure to chemicals. Geneva: World Health Organization, 1999). The dose of the test substance that causes acute hepatotoxicity predicted by the present invention completely falls within the range of the dose that causes hepatotoxicity in animal experiments. The prediction results are accurate and reliable, and can achieve the purpose of replacing animal acute hepatotoxicity. It shows that the replacement model established by the present invention can accurately predict the acute hepatotoxicity threshold of mice and can completely replace the acute hepatotoxicity experiment of mice. Comparison between the prediction results of the model of the present invention and the experimental results of mice. Figure 4 shown.

[0093] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A method for predicting changes in drug content in a living body, characterized in that: The method includes: Obtain the in vitro kinetic parameters of the test substance, the physicochemical property parameters of the test substance and the physiological parameters of the organism, calculate the maximum enzyme reaction rate of the test substance in the liver and / or small intestine based on the in vitro kinetic parameters of the test substance, and then predict the content change of the test substance in the organism through a physiological pharmacokinetic model that simulates the kinetic process of the drug in vivo; Wherein, the compartment structure of the physiological pharmacokinetic model simulating the kinetic process of the drug in vivo includes the gastrointestinal tract, small intestine, liver, slowly perfused tissue, quickly perfused tissue, fat and / or blood; The in vitro kinetic parameters of the test substance include the maximum enzyme reaction rate of the test substance in the in vitro microsomes and the Michaelis constant of the test substance in the in vitro microsomes; The content change of the test substance in the organism includes the content change of the test substance in the small intestine, liver, fat, fast perfusion tissue, slow perfusion tissue and / or blood; The microsomes include liver microsomes and / or small intestinal microsomes; The maximum enzyme reaction rate of the test substance in the in vitro microsomes and the Michaelis constant of the test substance in the in vitro microsomes are calculated based on the in vitro microsome experiments of the test substance.

2. The method according to claim 1, characterized in that: The physiological pharmacokinetic model simulating the kinetic process of the drug in vivo is established using a general calculus equation solver, and the physiological pharmacokinetic model contains a mass conservation differential equation describing the dynamic changes in the content of the test substance in each chamber structure every hour.

3. The method according to claim 2, characterized in that The mass conservation differential equation describing the dynamic changes of the test substance content in the small intestine every hour is shown in formula (1): ASi' = QSi×(CB-CVSi) + Ka×AGI-AMSiM2'(1), Among them, ASi' is the dynamic change of the test substance content in the small intestine per hour (µmol / h), QSi is the small intestinal blood flow (L / h), CB is the concentration of the test substance in the blood (µmol / L), CVSi is the concentration of the test substance flowing into the venous blood after metabolism in the small intestine (µmol / L), Ka is the absorption rate constant of the test substance in the intestine (h -1 ), AGI is the content of the test substance in the gastrointestinal tract (µmol), AMSiM2' is the dynamic change of the content of the metabolite of the test substance in the small intestine per hour (µmol / h); AMSiM2'=VmaxSiM2×CVSi / (KmSiM2+CVSi), VmaxSiM2 is the maximum enzyme reaction rate of the test substance in the small intestine (µmol / h), and KmSiM2 is the Michaelis constant of the test substance in the small intestinal microsomes in vitro (µmol / L).

4. The method according to claim 2, characterized in that: The mass conservation differential equation describing the dynamic changes of the test substance content in the liver every hour is shown in formula (2): AL' = QL×CB +QSi×CVSi-(QL+QSi)×CVL-AMLM1'(2), Among them, AL' is the dynamic change of the test substance content in the liver per hour (µmol / h), QL is the liver blood flow (L / h), QSi is the small intestine blood flow (L / h), CVSi is the concentration of the test substance flowing into the venous blood after metabolism in the small intestine (µmol / L), CVL is the concentration of the test substance flowing into the venous blood after metabolism in the liver (µmol / L), AMLM1' is the dynamic change of the test substance metabolite content in the liver per hour (µmol / h); AMLM1'=VmaxLM1×CVL / (KmLM1+CVL), VmaxLM1 is the maximum enzyme reaction rate of the test substance in the liver (µmol / h), and KmLM1 is the Michaelis constant of the test substance in in vitro liver microsomes (µmol / L).

5. The method according to claim 1, characterized in that The method further comprises drawing a time-concentration change curve of the test substance in the organism.

6. The method according to any one of claims 1 to 5, characterized in that: The test substance is a Senecio drug.

7. A device for predicting changes in drug content in a living body, which uses the method according to any one of claims 1 to 6 to predict changes in drug content in a living body, characterized in that: The device comprises: A data input module, used to input in vitro kinetic parameters of the test substance, physicochemical property parameters of the test substance and physiological parameters of the organism, wherein the in vitro kinetic parameters of the test substance include the maximum enzyme reaction rate of the test substance in in vitro microsomes and the Michaelis constant of the test substance in in vitro microsomes, the microsomes include liver microsomes and / or small intestinal microsomes, and the maximum enzyme reaction rate and Michaelis constant of the test substance in microsomes are calculated based on in vitro microsome experiments of the test substance; A data preprocessing module, used to calculate the maximum enzyme reaction rate of the test substance in the liver and / or small intestine according to the in vitro kinetic parameters of the test substance; The model prediction module is used to predict the content change of the test substance in the organism by simulating the physiological pharmacokinetic model of the drug's kinetic process in the body.

8. The device according to claim 7, characterized in that The device also includes an output module for outputting a threshold value of liver damage caused by the test substance.

9. An electronic device comprising a processor and a memory, characterized in that: The memory stores an executable code, and when the executable code is executed by the processor, the processor executes the method according to any one of claims 1 to 6.

10. A computer-readable storage medium having executable code stored thereon, characterized in that: When the executable code is executed by a processor of an electronic device, the processor is caused to execute the method according to any one of claims 1 to 6.

Citation Information

Patent Citations

  • Establishment method and application of loratadine PBPK model

    CN113077846A

  • Method for predicting in-vivo PK / PD change after Selpatinib combined medication through PBPK-RO model

    CN113990519A

  • Method and system for predicting SGLT inhibitor human body exposure and target part protein inhibition rate by using PBPK model

    CN115512788A

Cited By

  • Method and apparatus for predicting exposure characteristics and toxicity of foreign chemicals to the heart

    CN122889431A